We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP) (OTCBB: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to...
Pre-clinical studies demonstrate potential of FT-104, its novel psychedelic molecule, as preferable option for psychedelic therapies, with comparable potency to psilocybin and shorter duration4...
TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced...
TORONTO, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, and WHOOP...
AMSTERDAM, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) ("Field Trip"), a global leader in the development and delivery of technology-enabled psychedelic...
TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP) ("Field Trip"), one of the leaders in the development and delivery of psychedelic therapies, announced today that it...
NetworkNewsWire Editorial Coverage: Compelling evidence of the therapeutic benefits of psychedelic drugs appears in multiple scientific studies. Several clinical trials are underway in the United...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.05 | 1.05 | 1.05 | 0 | 0 | CS |
4 | 0 | 0 | 1.05 | 1.05 | 1.05 | 0 | 0 | CS |
12 | 0 | 0 | 1.05 | 1.05 | 1.05 | 0 | 0 | CS |
26 | 0 | 0 | 1.05 | 1.05 | 1.05 | 0 | 0 | CS |
52 | 0 | 0 | 1.05 | 1.05 | 1.05 | 0 | 0 | CS |
156 | -4.16 | -79.8464491363 | 5.21 | 5.21 | 0.96 | 185 | 2.27017239 | CS |
260 | -2.26 | -68.2779456193 | 3.31 | 9.88 | 0.96 | 15637 | 5.14969396 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions